Mondego Bio
Business Services · Portugal · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Cantanhede Technology Park Nucleus 4 Lot...Phone Number
+351 231410890Website
www.mondegobio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Mondego Bio
Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mondego Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Mondego Bio has recently received funding, and reach out quickly before it becomes old news!
Mondego Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Mondego Bio had a recent Job posting/layoffs
Earning: See what the market has to say on Mondego Bio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Mondego Bio is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Mondego Bio launches new products
Congratulate Masked Content for being promoted to Masked Content at Mondego Bio
Funding: Get notified immidiatlly once Mondego Bio has new funding data
Recommended Actions
Reach out to Masked Content who joined Mondego Bio as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Mondego Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Mondego Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Mondego Bio.
Mondego Bio financials insights
Gather financial insights about Mondego Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series A
$23.5M
Mondego Bio News & Media
ChemDiv Extends Discovery and Early Development Partnership with Mondego Bio on Best-in-Class PTPN2 Immuno-Oncology Program
SAN DIEGO, Oct. 24, 2025 /PRNewswire/ -- ChemDiv today announced the extension of its discovery and early development partnership with Mondego Bio to advance the company's best-in-class immuno-oncology program targeting PTPN2. The announcement follows Mondego Bio's successful Series A...Expert Systems Inc., a leading drug discovery accelerator, proudly announces the Series A funding and launch of Mondego Bio, an emerging immuno-oncology company headquartered at Biocant Park in Cantanhede, Portugal.
The new venture is backed by Biovance Capital, Torrey Pines Investment, and OrbiMed. Mondego Bio is advancing a portfolio of first- and best-in-class PTPN2 inhibitors designed to transform cancer immunotherapy. SAN DIEGO, Sept. 29, 2025 /PRNewswire/ -- Mondego Bio is strategically...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mondego Bio
Sign Up For FreeTo access detailed company insights
Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile.... Read More
